Lipid testing in infectious diseases: possible role in diagnosis and prognosis

Infection

Volumn 45, Issue 5, 2017, Pages 575-588

  Filippas Ntekouan, Sebastian ^a   Liberopoulos, Evangelos ^a   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cholesterol; Infection; Inflammation; Lipids; Sepsis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE 9; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; LIPID;

BACTERIAL INFECTION; DISEASE SEVERITY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INNATE IMMUNITY; LIPID BLOOD LEVEL; LIPID LEVEL; MEDLINE; NONHUMAN; PARASITOSIS; PATHOPHYSIOLOGY; PROGNOSIS; RESPIRATORY TRACT INFECTION; REVIEW; SYSTEMATIC REVIEW; TOTAL CHOLESTEROL LEVEL; TRIACYLGLYCEROL LEVEL; VIRUS INFECTION; COMMUNICABLE DISEASE; IMMUNOLOGY; MICROBIOLOGY; PARASITOLOGY; VIROLOGY;

COMMUNICABLE DISEASES; HUMANS; IMMUNITY, INNATE; LIPIDS; LIPOPROTEINS; PROGNOSIS;

EID: 85019034441     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-017-1022-3     Document Type: Review

References (124)

1. Piepoli MF, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;252:207–74.
2. Wendel M, Paul R, Heller AR. Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med. 2007;33:25–35.
3. Gallin JI, Kaye D, O’Leary WM. Serum lipids in infection. N Engl J Med. 1969;281:1081–6.
4. Grunfeld C, et al. Lipoproteins inhibit macrophage activation by lipoteichoic acid. J Lipid Res. 1999;40:245–52.
5. Alvarez C, Ramos A. Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem. 1986;32:142–5.
6. Morin EE, et al. HDL in sepsis—risk factor and therapeutic approach. Front Pharmacol. 2015;6:244.
7. Pirillo A, Catapano AL, Norata GD. HDL in infectious diseases and sepsis. Handb Exp Pharmacol. 2015;224:483–508.
8. Muramoto G, et al. Lipid profiles of children and adolescents with inflammatory response in a paediatric emergency department. Ann Med. 2016;48:323–9.
9. Norata GD, Pirillo A, Catapano AL. HDLs, immunity, and atherosclerosis. Curr Opin Lipidol. 2011;22:410–6.
10. Florentin M, et al. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008;23:370–8.
11. Pirillo A, Norata GD, Catapano AL. Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality. Curr Pharm Des. 2013;19:3841–57.
12. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342–74.
13. Guo L, et al. High density lipoprotein protects against polymicrobe-induced sepsis in mice. J Biol Chem. 2013;288:17947–53.
14. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma. J Clin Investig. 1981;67:827–37.
15. De Nardo D, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol. 2014;15:152–60.
16. Plociennikowska A, et al. Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2015;72:557–81.
17. Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev. 2003;16:379–414.
18. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216.
19. Castrillo A, et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell. 2003;12:805–16.
20. Wehmeier KR, et al. Inhibition of ABCA1 protein expression and cholesterol efflux by TNF alpha in MLO-Y4 osteocytes. Calcif Tissue Int. 2016;98:586–95.
21. Park Y, Pham TX, Lee J. Lipopolysaccharide represses the expression of ATP-binding cassette transporter G1 and scavenger receptor class B, type I in murine macrophages. Inflamm Res. 2012;61:465–72.
22. Jerala R. Structural biology of the LPS recognition. Int J Med Microbiol. 2007;297:353–63.
23. Yao Z, et al. Blood-borne lipopolysaccharide is rapidly eliminated by liver sinusoidal endothelial cells via high-density lipoprotein. 2016;197:2390–9.
24. Han R. Plasma lipoproteins are important components of the immune system. Microbiol Immunol. 2010;54:246–53.
25. Cohen J. Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme. Br Med Bull. 1999;55:212–25.
26. Vishnyakova TG, et al. Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J Biol Chem. 2003;278:22771–80.
27. Levels JH, et al. Distribution and kinetics of lipoprotein-bound lipoteichoic acid. Infect Immun. 2003;71:3280–4.
28. Hosoai H, et al. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J Lipid Res. 1999;40:648–53.
29. Feingold KR, Grunfeld C. The effect of inflammation and infection on lipids and lipoproteins. In: De Groot LJ, et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2000.
30. Khovidhunkit W, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45:1169–96.
31. de la Llera Moya M, et al. Inflammation modulates human HDL composition and function in vivo. Atherosclerosis. 2012;222:390–4.
32. Zewinger S, et al. Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur Heart J. 2015;36:3007–16.
33. Clifton PM, Mackinnon AM, Barter PJ. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J Lipid Res. 1985;26:1389–98.
34. Van Lenten BJ, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Investig. 1995;96:2758–67.
35. Feingold KR, Grunfeld C. Obesity and dyslipidemia. In: De Groot LJ, et al., editors. Endotext. South Dartmouth: MDText.com, Inc.; 2000.
36. Levels JH, et al. Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein. Infect Immun. 2005;73:2321–6.
37. Vreugdenhil AC, et al. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol. 2003;170:1399–405.
38. Flegel WA, et al. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun. 1993;61:5140–6.
39. Moorby CD, et al. Transforming growth factor-beta 1 and interleukin-1 beta stimulate LDL receptor activity in Hep G2 cells. Atherosclerosis. 1992;97:21–8.
40. Liao W, Floren CH. Tumor necrosis factor up-regulates expression of low-density lipoprotein receptors on HepG2 cells. Hepatology. 1993;17:898–907.
41. Topchiy E, et al. Lipopolysaccharide is cleared from the circulation by hepatocytes via the low density lipoprotein receptor. PLoS One. 2016;11:e0155030.
42. Zhang DW, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282:18602–12.
43. Walley KR. et al, PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med. 2014;6:258ra143.
44. Ruscica M, et al. Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J Biol Chem. 2016;291:3508–19.
45. Erqou S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–23.
46. Ramharack R, Barkalow D, Spahr MA. Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol. 1998;18:984–90.
47. Wade DP, et al. 5′ control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci USA. 1993;90:1369–73.
48. Mooser V, et al. Major reduction in plasma Lp(a) levels during sepsis and burns. Arterioscler Thromb Vasc Biol. 2000;20:1137–42.
49. Liberopoulos E, et al. Severe hypocholesterolemia with reduced serum lipoprotein(a) in a patient with visceral leishmaniasis. Ann Clin Lab Sci. 2002;32:305–8.
50. Barcia AM, Harris HW. Triglyceride-rich lipoproteins as agents of innate immunity. Clin Infect Dis. 2005;41:S498–503.
51. Feingold KR, et al. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res. 1992;33:1765–76.
52. Feingold KR, Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Investig. 1987;80:184–90.
53. Feingold KR, et al. Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler Thromb. 1994;14:1866–72.
54. Grunfeld C, et al. Mechanisms by which tumor necrosis factor stimulates hepatic fatty acid synthesis in vivo. J Lipid Res. 1988;29:1327–35.
55. Feingold KR, et al. Diet affects the mechanisms by which TNF stimulates hepatic triglyceride production. Am J Physiol. 1990;259:E177–84.
56. Beylot M, et al. Regulation of ketone body flux in septic patients. Am J Physiol. 1989;257:E665–74.
57. Memon RA, et al. Differential effects of interleukin-1 and tumor necrosis factor on ketogenesis. Am J Physiol. 1992;263:E301–9.
58. Lu B, et al. The acute phase response stimulates the expression of angiopoietin like protein 4. Biochem Biophys Res Commun. 2010;391:1737–41.
59. Aguiar C, et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: a report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler Suppl. 2015;19:1–12.
60. Christoffersen C, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA. 2011;108:9613–8.
61. Ronsein GE, Vaisar T. Inflammation, remodeling, and other factors affecting HDL cholesterol efflux. Curr Opin Lipidol. 2017;28:52–9.
62. Funderburg NT, Mehta NN. Lipid abnormalities and inflammation in HIV inflection. Curr HIV/AIDS Rep. 2016;13:218–25.
63. Chien JY, et al. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med. 2005;33:1688–93.
64. Barlage S, et al. Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation. Intensive Care Med. 2009;35:1877–85.
65. Vermont CL, et al. Serum lipids and disease severity in children with severe meningococcal sepsis. Crit Care Med. 2005;33:1610–5.
66. Fraunberger P, et al. Serum cholesterol levels in neutropenic patients with fever. Clin Chem Lab Med. 2002;40:304–7.
67. Zou G, et al. The delta high-density lipoprotein cholesterol ratio: a novel parameter for gram-negative sepsis. Springerplus. 2016;5:1044.
68. Rodriguez-Sanz A, et al. High-density lipoprotein: a novel marker for risk of in-hospital infection in acute ischemic stroke patients? Cerebrovasc Dis. 2013;35:291–7.
69. Guirgis FW, et al. Cholesterol levels and long-term rates of community-acquired sepsis. Crit Care. 2016;20:408.
70. Rodriguez Reguero JJ, et al. Variation in plasma lipid and lipoprotein concentrations in community-acquired pneumonia a six-month prospective study. Eur J Clin Chem Clin Biochem. 1996;34:245–9.
71. Gruber M, et al. Prognostic impact of plasma lipids in patients with lower respiratory tract infections—an observational study. Swiss Med Wkly. 2009;139:166–72.
72. Chien YF, et al. Decreased serum level of lipoprotein cholesterol is a poor prognostic factor for patients with severe community-acquired pneumonia that required intensive care unit admission. J Crit Care. 2015;30:506–10.
73. Apostolou F, et al. Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella. J Lipid Res. 2009;50:2532–9.
74. Gazi IF, et al. Leptospirosis is associated with markedly increased triglycerides and small dense low-density lipoprotein and decreased high-density lipoprotein. Lipids. 2011;46:953–60.
75. Peces R. Acute renal failure in severe leptospirosis. Nephrol Dial Transplant. 2003;18:1235–6.
76. Liberopoulos E, Apostolou F, Elisaf M. Serum lipid profile in patients with severe leptospirosis. Nephrol Dial Transplant. 2004;19:1328–9 (author reply 1329–30).
77. Kim TJ, et al. Helicobacter pylori is associated with dyslipidemia but not with other risk factors of cardiovascular disease. Sci Rep. 2016;6:38015.
78. Longo-Mbenza B, et al. Helicobacter pylori infection is identified as a cardiovascular risk factor in Central Africans. Vasc Health Risk Manag. 2012;6:455–61.
79. Calza L, et al. Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2016;71:1451–65.
80. Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut. 2010;59:1279–87.
81. Wang CC, Tseng TC, Kao JH. Hepatitis B virus infection and metabolic syndrome: fact or fiction? J Gastroenterol Hepatol. 2015;30:14–20.
82. Apostolou F, et al. Acute infection with Epstein–Barr virus is associated with atherogenic lipid changes. Atherosclerosis. 2010;212:607–13.
83. Fleck-Derderian S, McClellan W, Wojcicki JM. The association between cytomegalovirus infection, obesity, and metabolic syndrome in U.S. adult females. Obesity (Silver Spring). 2017;25:626–33.
84. Biswas HH, et al. Lower low-density lipoprotein cholesterol levels are associated with severe dengue outcome. PLoS Negl Trop Dis. 2015;9:e0003904.
85. Faustino AF, et al. Dengue virus capsid protein interacts specifically with very low-density lipoproteins. Nanomedicine. 2014;10:247–55.
86. Non LR, Escota GV, Powderly WG. HIV and its relationship to insulin resistance and lipid abnormalities. Transl Res. 2017:183:41–56.
87. Constans J, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Investig. 1994;24:416–20.
88. El-Sadr WM, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005;6:114–21.
89. Mujawar Z, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006;4:e365.
90. Shrivastav S, et al. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor gamma and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol. 2008;22:234–47.
91. Gavrilova O, et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem. 2003;278:34268–76.
92. Carr A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–9.
93. Dave JA, et al. Anti-retroviral therapy increases the prevalence of dyslipidemia in South African HIV-infected patients. PLoS One. 2016;11:e0151911.
94. Wang Y, et al. The mechanism of apoliprotein A1 down-regulated by Hepatitis B virus. Lipids Health Dis. 2016;15:64.
95. Zhu C, et al. Hepatitis B virus inhibits apolipoprotein A5 expression through its core gene. Lipids Health Dis. 2016;15:178.
96. Jarcuska P, et al. Association between hepatitis B and metabolic syndrome: current state of the art. World J Gastroenterol. 2016;22:155–64.
97. Kang SK, et al. The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III. J Biol Chem. 2004;279:28106–12.
98. Lucifora J, Esser K, Protzer U. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Res. 2013;97:195–7.
99. Bassendine MF, et al. Lipids and HCV. Semin Immunopathol. 2013;35:87–100.
100. Domitrovich AM, Felmlee DJ, Siddiqui A. Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion. J Biol Chem. 2005;280:39802–8.
101. Moriya K, et al. Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol Res. 2003;25:371–6.
102. Rowell J, et al. Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatol Int. 2012;6:475–81.
103. Huang H, et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA. 2007;104:5848–53.
104. Podevin P, et al. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology. 2010;139:1355–64.
105. Farquhar MJ, Harris HJ, McKeating JA. Hepatitis C virus entry and the tetraspanin CD81. Biochem Soc Trans. 2011;39:532–6.
106. Le QT, et al. Plasma membrane tetraspanin CD81 complexes with proprotein convertase subtilisin/kexin type 9 (PCSK9) and low density lipoprotein receptor (LDLR), and its levels are reduced by PCSK9. J Biol Chem. 2015;290:23385–400.
107. Oliveira C, et al. Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles. Hepatology. 2017. doi:10.1002/hep.29096
108. Agouridis AP, et al. New-onset extremely low levels of high-density lipoprotein cholesterol. J Clin Lipidol. 2012;6:593–5.
109. Liberopoulos EN, et al. Visceral leishmaniasis is associated with marked changes in serum lipid profile. Eur J Clin Investig. 2014;44:719–27.
110. Lal CS, et al. Hypertriglyceridemia: a possible diagnostic marker of disease severity in visceral leishmaniasis. Infection. 2016;44:39–45.
111. Flores MS, et al. Hypocholesterolemia in patients with an amebic liver abscess. Gut Liver. 2014;8:415–20.
112. Bansal D, Bhatti HS, Sehgal R. Altered lipid parameters in patients infected with Entamoeba histolytica, Entamoeba dispar and Giardia lamblia. Br J Biomed Sci. 2005;62:63–5.
113. Visser BJ, et al. Serum lipids and lipoproteins in malaria—a systematic review and meta-analysis. Malar J. 2013;12:442.
114. Caldas IR, et al. Human schistosomiasis mansoni: immune responses during acute and chronic phases of the infection. Acta Trop. 2008;108:109–17.
115. Gryseels B. Schistosomiasis. Infect Dis Clin N Am. 2012;26:383–97.
116. Yokoyama S, Okumura-Noji K, Lu R. Prevention of fatal hepatic complication in schistosomiasis by inhibition of CETP. J Biomed Res. 2015;29:176–88.
117. Rumjanek FD, Campos EG, Afonso LC. Evidence for the occurrence of LDL receptors in extracts of schistosomula of Schistosoma mansoni. Mol Biochem Parasitol. 1988;28:145–52.
118. Duchateau PN, et al. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem. 1997;272:25576–82.
119. Tada H, Kawashiri MA, Yamagishi M. Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants. J Hum Genet. 2017;62:453–58.
120. Moutzouri E, Elisaf M, Liberopoulos EN. Hypocholesterolemia. Curr Vasc Pharmacol. 2011;9:200–12.
121. Devaud JC, et al. Does the type of parenteral lipids matter? A clinical hint in critical illness. Clin Nutr. 2017;36:491–96.
122. Fattore E, et al. Effects of free sugars on blood pressure and lipids: a systematic review and meta-analysis of nutritional isoenergetic intervention trials. Am J Clin Nutr. 2017;105:42–56.
123. Druml W, et al. Lipid metabolism in acute renal failure. Kidney Int Suppl. 1983;16:S139–42.
124. Etogo-Asse FE, et al. High density lipoprotein in patients with liver failure; relation to sepsis, adrenal function and outcome of illness. Liver Int. 2012;32:128–36.